Edition:
United Kingdom

Akorn Inc (AKRX.OQ)

AKRX.OQ on NASDAQ Stock Exchange Global Select Market

3.61USD
6:33pm GMT
Change (% chg)

$-0.03 (-0.82%)
Prev Close
$3.64
Open
$3.65
Day's High
$3.67
Day's Low
$3.57
Volume
164,469
Avg. Vol
1,068,354
52-wk High
$33.50
52-wk Low
$3.15

Chart for

About

Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $4,101.01
Shares Outstanding(Mil.): 124.92
Dividend: --
Yield (%): --

Financials

  AKRX.OQ Industry Sector
P/E (TTM): 33.22 30.48 33.71
EPS (TTM): 0.99 -- --
ROI: 6.80 14.98 14.48
ROE: 14.90 16.31 15.99

Akorn gets FDA warning letter for Illinois plant, shares drop

Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year.

09 Jan 2019

UPDATE 3-Akorn gets FDA warning letter for Illinois plant, shares drop

Jan 9 Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year.

09 Jan 2019

Akorn gets warning letter from the FDA

Jan 9 Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration, after the company's Decatur, Illinois manufacturing facility was inspected by the regulatory authority in April and May, 2018.

09 Jan 2019

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

WILMINGTON, Del Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE .

07 Dec 2018

Akorn to Delaware justices: Chancery’s MAC opinion is ‘new blueprint for remorseful buyers’

The global pharmaceutical company Fresenius received a rude shock in the summer of 2017 when Akorn, the generic drugmaker Fresenius had agreed to acquire for $4.75 billion, reported its quarterly financial results. The results were terrible – far worse than Fresenius’ gloomiest projection. Fresenius CEO Stephan Sturm considered the Akorn results the biggest personal embarrassment of his career. Within weeks, the company hired Paul Weiss Rifkind Wharton & Garrison to advise it could w

31 Oct 2018

Trade pact lifts European shares while Italy extends slide

LONDON European shares rose on Monday as a new U.S.-Mexico-Canada trade pact lifted some of the gloom over global trade, while Italian stocks extended Friday's slide as top EU officials weighed in on the government's budget plans.

01 Oct 2018

UPDATE 2-Trade pact lifts European shares while Italy extends slide

* Fresenius jumps 8.5 pct after Akorn ruling win (Updates prices, adds details)

01 Oct 2018

Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal

WILMINGTON, Del Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

01 Oct 2018

Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal

WILMINGTON, Del Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

01 Oct 2018

REFILE-UPDATE 2-Delaware judge says Fresenius can walk away from $4.8 bln Akorn deal

WILMINGTON, Del, Oct 1 Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

01 Oct 2018

Earnings vs. Estimates